Determination of vortioxetine in human serum and saliva samples by HPLC–DAD and HPLC–MS

• Autorzy: Wróblewski K. , Petruczynik A. , Buszewski B. , Szultka-Młyńska M. , Karakuła-Juchnowicz H. , Waksmundzka-Hajnos M.

Identyfikatory

DOI

10.1556/1326.2017.29.3.02

• Języki publikacji: EN

Abstrakty

EN

Vortioxetine is a new drug against major depressive disorder with high affinity for a range of different serotonergic targets in the central nervous system. Therapeutic drug monitoring is an important tool for the clinical management of patients receiving a pharmacotherapy, particularly in psychiatry. For this reason, determination of drug concentration in biological fluids is important for a rational dosage of drugs. Rapid and reliable analytical assays are also required to detect and identify drugs of toxicological importance. For analysis of vortioxetine by high-performance liquid chromatography (HPLC), no procedures for its determination in saliva have been reported and there are only a few ones for its determination in serum. A sensitive and selective highperformance liquid chromatography with diode array detector (HPLC-DAD) or mass spectrometer (HPLC-MS) method was developed for the fast quantification of vortioxetine in human saliva and serum. The determination was performed on a Synergi Polar RP column in isocratic mode under the optimal mobile phase containing 70% methanol, 20% acetate buffer at pH 3.5, 10% double distilled water, and 0.025 M L−1 diethylamine.

Słowa kluczowe

EN

vortioxetine; HPLC-DAD; HPLC-MS; human serum; human saliva

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2017
• Tom: Vol. 29, no. 3
• Strony: 325--344
• Opis fizyczny: Bibliogr. 14 poz.

Twórcy

autor

Wróblewski K.

• Department of Inorganic Chemistry Medical University of Lublin, Chodźki 4a 20-093 Lublin, Poland

autor

Petruczynik A.

• Department of Inorganic Chemistry Medical University of Lublin, Chodźki 4a 20-093 Lublin, Poland

autor

Buszewski B.

• Department of Environmental Chemistry and Bioanalytics, Nicolaus Copernicus University, Faculty of Chemistry Gagarina 7, PL-87-100 Toruń, Poland

autor

Szultka-Młyńska M.

• Centre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, Wileńska 4, Toruń, Poland

autor

Karakuła-Juchnowicz H.

• Department of Clinical Neuropsychiatry, Medical University of Lublin, Głuska 2, 20-439 Lublin, Poland

autor

Waksmundzka-Hajnos M.

• Department of Inorganic Chemistry Medical University of Lublin, Chodźki 4a 20-093 Lublin, Poland

Bibliografia

• [1] L. Pehrson, S.C. Leiser, M. Gulinello, E. Dale, Y. Li, J.A. Waller, and C. Sanchez, Eur. J. Pharmacol., 753, 19 (2015)
• [2] A. Mørk, L.P. Montezinho, S. Miller, C. Trippodi-Murphy, N. Plath, Y. Li, M. Gulinello, and C. Sanchez, Pharmacol. Biochem. Be., 105, 41 (2013)
• [3] J.B. Jensen, K.G. Jardin, D. Song, D. Budac, G. Smagin, C. Sanchez, and A.L. Pehrsonn, Eur. Neuropsychopharma., 24, 148 (2014)
• [4] K.A. Connors, T.W. Valenti, K. Lawless, J. Sackerman, E.S. Onaivi, B.W. Brooks, and G.G. Goulde, Aquat. Toxicol., 151, 105 (2014)
• [5] G. Chen, R. Lee, A.-M. Højer, J.K. Buchbjerg, M. Serenko, and Z. Zhao, Clin. Drug Investig., 33, 727 (2013)
• [6] A.L. Pehrson, T. Cremers, C. Betry, M.G.C. van der Hart, L. Jørgensena, M. Madsen, N. Haddjeri, and B. Ebert, Eur. Neuropsychopharm., 23, 133 (2013)
• [7] C. Bétry, A. Etiévant, A. Pehrson, C. Sánchez, and N. Haddjeri, Prog. Neuro- Psychoph., 58, 38 (2015)
• [8] H.J. Möller, Eur. Arch. Psychiatry Clin. Neurosci., 256, 476 (2006)
• [9] P. Stenkrona, C. Halldin, and J. Lundberg, Eur. Neuropsychopharm., 23, 1190 (2013)
• [10] G. Chen, R. Lee, A.-M. Højer, J.K. Buchbjerg, M. Serenko, and Z. Zhao, Clin. Drug Investig., 33, 727 (2013)
• [11] E-m. Gu, C. Huang, B. Liang, L. Yuan, T. Lan, G. Hu, and H. Zhou, J. Chromatogr. B, 997, 70 (2015)
• [12] C. Sanchez, K.E. Asin, and F. Artigas, Pharmacol. Ther., 145, 43 (2015)
• [13] E-m. Gu, C. Huang, B. Liang, L. Yuan, T. Lan, G. Hu, and H. Zhou, J. Chromatogr. B, 997, 70–74 (2015)
• [14] C. Sanchez, K.E. Asin, and F. Artigas, Pharmacol. Ther., 145, 43–57 (2015).

Uwagi

PL

Opracowanie ze środków MNiSW w ramach umowy 812/P-DUN/2016 na działalność upowszechniającą naukę (zadania 2017).